Chief Financial Officer Kim Joanne Wendy covered exercise/tax liability with 23,202 shares and was granted 73,000 shares, increasing direct ownership by 113% to 93,940 units (SEC Form 4)

$BIVI
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $BIVI alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
KIM JOANNE WENDY

(Last) (First) (Middle)
C/O BIOVIE INC.
680 W NYE LANE STE 201

(Street)
CARSON CITY NV 89703

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIOVIE INC. [ BIVI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/16/2023
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/16/2023 F 2,476 D $5.51 41,672 D
Common Stock 02/15/2024 F 2,476 D $1.18 39,196 D
Common Stock 06/24/2024(1) A 73,000 A $0 112,196 D
Common Stock 06/24/2024(1) F 18,250 D $0.474 93,940 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $0.474 06/24/2024 A 99,000 (2) 06/24/2034 Common Stock 99,000 $0 99,000 D
Explanation of Responses:
1. The restricted stock unit ("RSU") grant was approved by the compensation committee of the issuer's board of directors on June 10, 2024, which grant became effective on June 24, 2024. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vested in full on June, 24, 2024.
2. The options vest in three equal annual installments beginning on June 24, 2024.
/S/ JOANNE WENDY KIM 07/12/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $BIVI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BIVI

DatePrice TargetRatingAnalyst
7/22/2022$7.00Overweight
Cantor Fitzgerald
11/30/2021$50.00 → $27.00Buy
B. Riley Securities
More analyst ratings

$BIVI
Press Releases

Fastest customizable press release news feed in the world

See more
  • BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025

    CARSON CITY, Nev., March 27, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a virtual investor event featuring key opinion leader (KOL) Lindsay McAlpine, MD, BSc (Yale University), who will join company management to discuss the unmet need and current treatment landscape for long COVID on Thursday, April 10, 2025 at 10:00 AM ET. To register, click here. The event will provide an update on BioVie's ADDRESS-LC trial evaluating bezisterim (NE3107) for the treatment of

    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

    CARSON CITY, Nev., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract on the design of its planned Phase 2 trial evaluating bezisterim in Long COVID has been accepted as a poster presentation at the Demystifying Long COVID International Conference, November 21st & 22nd 2024, in Barcelona Spain. The planned Phase 2 study, which is fully funded by a grant from the U.S. Department of Defense (DOD), is a double-blind, randomized (1:1), placebo-controlled, multicenter t

    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • BioVie's Upcoming Parkinson's Disease Clinical Trial is Fully Funded

    CARSON CITY, Nev., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, is pleased to announce that the upcoming PD-202 A Double-Blind, Randomized, Placebo-controlled, Study of Bezisterim in Subjects with Early Parkinson's Disease is now fully funded. Favorable capital market conditions last week enabled the company to raise over $15 million from secondary offerings, and the proceeds allow the Company to fund fully the costs of this upcoming clinical trial. The trial is expected to start in ea

    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BIVI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BIVI
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$BIVI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BIVI
SEC Filings

See more

$BIVI
Leadership Updates

Live Leadership Updates

See more
  • BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID

    CARSON CITY, Nev., June 04, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the formation of a long COVID Advisory Board that will provide the Company with strategic guidance on the design and execution of a Phase 2b trial in patients with long COVID, with funding from the U.S. Department of Defense. Long COVID is a condition in which symptoms of COVID-19, the acute respiratory disease caused by the SARS-CoV-2 virus, persist for an extended period of time, generally three months or

    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • BioVie Announces the Appointment of a New Chief Medical Officer

    RENO, Nev., Nov. 01, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurodegenerative disease - announced today the appointment of Joseph M. Palumbo, MD, LFAPA, MACPsych, as the Company's new Chief Medical Officer. In this role Dr. Palumbo will oversee the Company's clinical development and operations activities, including the advancement of NE3107, an oral small molecule, blood-brain permeable modulator of ERK and NFkB (e.g. TNF transcription) expected to modulate neuroinflammation and insulin resistance, while still facilitating the homeostatic function inherent to their mechanisms (

    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • BioVie Acquires Biopharma Assets from Privately Held NeurMedix

    Includes Pivotal Phase 3 Alzheimer's Asset NE3107 Cuong V. Do Named CEO of The New BioVie Conference Call Scheduled for April 27, 2021 at 5:00PM EDT SANTA MONICA, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for chronic debilitating liver diseases, today announced the acquisition of the biopharmaceutical assets of NeurMedix, Inc., (NeurMedix), a San Diego based privately held clinical-stage pharmaceutical company focused on novel therapeutic assets for the treatment of neurodegenerative and neurological disorders, as well as certain cancers. Under the terms of the agreeme

    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BIVI
Financials

Live finance-specific insights

See more
  • BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

    CARSON CITY, Nev., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract on the design of its planned Phase 2 trial evaluating bezisterim in Long COVID has been accepted as a poster presentation at the Demystifying Long COVID International Conference, November 21st & 22nd 2024, in Barcelona Spain. The planned Phase 2 study, which is fully funded by a grant from the U.S. Department of Defense (DOD), is a double-blind, randomized (1:1), placebo-controlled, multicenter t

    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

    Patents covering BioVie's terlipressin liquid formulation now secured in the United States, India, Japan and Chile, and are pending in eight additional markets Liquid formulation has demonstrated room-temperature stability for up to 24 months, representing an important advantage for treating patients with cirrhosis and ascites in the home-care setting CARSON, Nev., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it has received a Notice of Allowance from the Japan

    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    ORLANDO, FL / ACCESSWIRE / October 11, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and Genetic Technologies Limited (NASDAQ:GENE)(ASX:GTG) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessGenetic Technologies: https://www.redchip.com/assets/access/gene_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical prog

    $BIVI
    $BOXL
    $GENE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Other Consumer Services
    Real Estate

$BIVI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more